Skip to main content

Research Repository

Advanced Search

The use of ?2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis

Patel, Mitesh; Pilcher, Janine; Hancox, Robert J.; Sheahan, Davitt; Pritchard, Alison; Braithwaite, Irene; Shaw, Dominick; Black, Peter; Weatherall, Mark; Beasley, Richard

Authors

Mitesh Patel

Janine Pilcher

Robert J. Hancox

Davitt Sheahan

Alison Pritchard

Irene Braithwaite

Peter Black

Mark Weatherall

Richard Beasley



Abstract

Background:
Patterns of inhaled β2-agonist therapy use during severe asthma exacerbations before hospital attendance are poorly understood.

Aims:
To assess β2-agonist use prior to hospital attendance.

Methods:
We undertook an exploratory post hoc analysis of data from a 6-month clinical trial of 303 patients randomised to combination budesonide/formoterol inhaler according to a Single combination inhaler as Maintenance And Reliever Therapy regimen (‘SMART’) or fixed-dose budesonide/formoterol with salbutamol as reliever (‘Standard’). Patterns of β2-agonist use for 14 days before hospital attendance with a severe asthma exacerbation were determined by electronic monitoring of inhaler use.

Results:
There were 22 hospital attendances in 16 patients during the study. Seven and nine hospital attendances were eligible for analysis in the SMART and Standard groups, respectively. In both regimens, β2-agonist use increased before hospital attendance, with a median (range) maximum daily number of actuations of 14 (9 to 63) budesonide/formoterol in SMART and 46 (6 to 95) salbutamol in Standard with 4 (0 to 10) budesonide/formoterol actuations on the day of maximal salbutamol use. There was delay in obtaining medical review despite high β2-agonist use, in 9/16 patients.
Different patterns of use were observed, including repeated days of no inhaled corticosteroid despite marked salbutamol use, which occurred in 3/9 patients in the Standard group.

Conclusions:
Delay in obtaining medical review in association with high β2-agonist use is common in patients before hospital presentation with severe exacerbations of asthma. The SMART regimen reduced nonadherence with inhaled corticosteroid therapy during severe exacerbations.

Citation

Patel, M., Pilcher, J., Hancox, R. J., Sheahan, D., Pritchard, A., Braithwaite, I., …Beasley, R. (2015). The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis. npj Primary Care Respiratory Medicine, 25, 1-9. https://doi.org/10.1038/npjpcrm.2014.99

Journal Article Type Article
Acceptance Date Aug 4, 2014
Online Publication Date Jan 8, 2015
Publication Date Jan 8, 2015
Deposit Date Oct 24, 2016
Publicly Available Date Oct 24, 2016
Journal npj Primary Care Respiratory Medicine
Electronic ISSN 2055-1010
Publisher Nature Publishing Group
Peer Reviewed Peer Reviewed
Volume 25
Article Number 14099
Pages 1-9
DOI https://doi.org/10.1038/npjpcrm.2014.99
Public URL https://nottingham-repository.worktribe.com/output/985285
Publisher URL http://www.nature.com/articles/npjpcrm201499

Files




You might also like



Downloadable Citations